CN102988278A - Bromfenac sodium hydrate eye drops and preparation method thereof - Google Patents
Bromfenac sodium hydrate eye drops and preparation method thereof Download PDFInfo
- Publication number
- CN102988278A CN102988278A CN2011102787484A CN201110278748A CN102988278A CN 102988278 A CN102988278 A CN 102988278A CN 2011102787484 A CN2011102787484 A CN 2011102787484A CN 201110278748 A CN201110278748 A CN 201110278748A CN 102988278 A CN102988278 A CN 102988278A
- Authority
- CN
- China
- Prior art keywords
- water
- bromfenac sodium
- sodium hydrate
- bromfenac
- eye drop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses eye drops and a preparation method thereof, and particularly relates to bromfenac sodium hydrate eye drops and a preparation method thereof. The bromfenac sodium hydrate eye drops comprise the following constituents in percentage by weight: 0.1-0.2% of bromfenac sodium hydrate, 0.1-0.3% of Tween-80, 1-5% of povidone, 0.01-0.03% of edetate disodium, 0.2-0.5% of anhydrous sodium sulfite, 0.01-0.02% of benzalkonium bromide, 0.005-0.02% of boric acid, 0.005-0.02% of borax, 0.002-0.01% of sodium hydroxide, and the balance of water.
Description
Technical field:
The present invention relates to a kind of eye drop and preparation method thereof, more particularly, relate to bromfenac sodium hydrate eye drop and preparation method thereof.
Background technology:
Bromfenac sodium is 2-amino-3-benzoylphenylacetic acids analog derivative, has anti-inflammatory analgesic action.Pharmacological evaluation shows that bromfenac sodium has antiinflammatory action to the impatient property of the rat experiment conjunctiva edema due to arachidonic acid, the carrageenin; Suppress almost completely that the aqueous humor protein concentration due to the laser irradiation increases behind the rabbit paracentesis of anterior chamber.But bromfenac sodium is unstable in water, bromfenac sodium is prepared into eye drop at first will solves unstable this problem in water.Yet if bromfenac sodium is too stable in water, the time resident in eye is long, can produce larger zest to eyes again.
Summary of the invention:
The present invention is exactly for the problems referred to above, and a kind of bromfenac sodium hydrate eye drop and preparation method thereof is provided.
In order to realize above-mentioned purpose of the present invention, the present invention adopts following technical scheme, and its composition and weight proportion 100% counted, bromfenac sodium hydrate 0.1～0.2%, Tween 80 is 0.1～0.3%, polyvidone 1～5%, disodium edetate 0.01～0.03%, anhydrous sodium sulfite 0.2～0.5%, benzalkonium bromide 0.01～0.02%, boric acid 0.005-0.02%, Borax 0.005-0.02%, sodium hydroxide 0.002-0.01%, surplus is water.
The composition of described eye drop and weight proportion are preferably in 100%, bromfenac sodium hydrate 0.1035%, Tween 80 are 0.15%, polyvidone 2%, disodium edetate 0.02%, anhydrous sodium sulfite 0.2%, benzalkonium bromide 0.01%, boric acid 0.02%, Borax 0.02%, sodium hydroxide 0.005%, and surplus is water.
Described water is water for injection.
The preparation method of eye drop is,
(1) dense joining: in dense preparing tank, add the water that accounts for water gross weight 1/5-1/3, the bromfenac sodium hydrate, Tween 80, disodium edetate, anhydrous sodium sulfite, the benzalkonium bromide that add simultaneously the described formula ratio of claim 1, be stirred to evenly, leave standstill 30-60min and filter by filter, filtrate is delivered to dilute preparing tank;
(2) rare joining: in dilute preparing tank, add the water that accounts for water gross weight 1/4-1/2, the boric acid, Borax, the polyvidone that add simultaneously the described formula ratio of claim 1, the surplus water is supplied, and adds the pH=8.0-8.6 of sodium hydroxide regulation system, continue to stir 20-40 minute even to medicinal liquid;
(3) check, filtration sterilization, embedding, lamp inspection, packing, full inspection.
The filtration sterilization operation of step (3) is selected microporous filter membrane, and the aperture is 0.22～0.45 μ m.
Beneficial effect of the present invention:
The eye drop that the present invention makes is mainly used in the symptomatic treatment of the diseases associated with inflammation of outer eye and front eye: blepharitis, conjunctivitis, strong film scorching (comprising that strong film is scorching), post-operation inflammatory etc.
The nonsteroidal anti-inflammatory eye drop of commonly using clinically now has 1% indomethacin, 0.1% diclofenac, 0.03% flurbiprofen, 1% suprofen, 0.5% ketoprofen eye drop etc., and using method all is 4 times/days.And the present invention only needs 2 times/days, and curative effect is good, and the ocular side effect incidence rate is very low, and the side effect incidence rate only is 3.78%.
The specific embodiment:
Embodiment 1
In dense preparing tank, add the 3000g injection water, add simultaneously bromfenac sodium hydrate 10.35g, Tween 80 is 15g, disodium edetate 2g, anhydrous sodium sulfite 20g, benzalkonium bromide 1g, be stirred to evenly, leave standstill 30min and filter by filter, filtrate is delivered to dilute preparing tank;
Add the 3000g injection water in the dilute preparing tank, add simultaneously boric acid 0.5g, Borax 0.5g, polyvidone 200g, continue to add water and mend to 10000g, add the pH=8.0 of sodium hydroxide regulation system, continue to stir 20 minutes even to medicinal liquid;
(3) check, filtration sterilization, embedding, lamp inspection, packing, full inspection, the filtration sterilization operation is selected microporous filter membrane, and the aperture is 0.45 μ m.
Embodiment 2
In dense preparing tank, add the 2000g injection water, add simultaneously bromfenac sodium hydrate 10g, Tween 80 is 10g, disodium edetate 3g, anhydrous sodium sulfite 40g, benzalkonium bromide 2g, be stirred to evenly, leave standstill the 40min time to filter by filter, filtrate is delivered to dilute preparing tank;
Add the 3000g injection water in the dilute preparing tank, add simultaneously boric acid 1g, Borax 2g, polyvidone 400g, continue to add water and mend to 10000g, add the pH=8.4 of sodium hydroxide regulation system, continue to stir 20 minutes even to medicinal liquid;
(3) check, filtration sterilization, embedding, lamp inspection, packing, full inspection, the filtration sterilization operation is selected microporous filter membrane, and the aperture is 0.22 μ m.
Embodiment 3
Add the 2500g injection water in the dense preparing tank, add simultaneously bromfenac sodium hydrate 20g, Tween 80 is 30g, disodium edetate 2g, anhydrous sodium sulfite 50g, benzalkonium bromide 1g, is stirred to evenly, leaves standstill 60min and filters by filter, filtrate is delivered to dilute preparing tank;
Add the 2500g injection water in the dilute preparing tank, add simultaneously boric acid 2g, Borax 1.5g, polyvidone 100g, continue to add water and mend to 10000g, add the pH=8.6 of sodium hydroxide regulation system, continue to stir 20 minutes even to medicinal liquid;
(3) check, filtration sterilization, embedding, lamp inspection, packing, full inspection, the filtration sterilization operation is selected microporous filter membrane, and the aperture is 0.22 μ m.
The irritant test of application examples 1 lagophthalmos eyeball
Raw material: the eye drop that makes take embodiment 1 carries out irritant test as sample to the new zealand rabbit eyes.5 of new zealand rabbits, regular grade, male 2, is provided laboratory animal occupancy permit number by female 3 by the anti-Pharmaceutical Group company limited in Shandong, Shandong: SYXK (Shandong) 20080002, signed and issued body weight 2.40-2.50kg by Shandong Province science and technology bureau.The blank adjuvant of sodium bromophenolate eye drops.
Preparation before the test:
Receive: after animal is bought, inspect for acceptance.After the acceptance(check), directly be transported between the rabbit quarantine, single cage is raised, and fills in laboratory animal and receives single.
Sign: adopting the method for cage label and auricle internal labeling numeral to identify, is No. 1 rabbit in No. 1 cage, and annotating in the auricle of rabbit with marking pen is to be No. 2 rabbit in 1, No. 2 cage, and notes are 2, successively the 3-5 rabbit are distinguished labelling.(1-3 number is female, and 4-5 is male.)
Quarantine: quarantine content and result are as follows:
● fur is glossy, without depilation phenomenon ● eye, nose, ear are on every side without secretions
● each one of health is without injuring inflammation outward ● behavior and gait, autonomic activities are normal
● defecation is normal ● it is normal to ingest, drink water
When begin quanrantine and finish, animal is weighed, and carry out the record of weighing.Every day the itemized record animal the clinical manifestation symptom.Quarantine is pre-raised after 7 days, the qualified animal of quarantine is moved between the rabbit raising raise.
Test method:
5 rabbit are numbered respectively 1-5 number, and left eye gives the eye drop that embodiment 1 obtains, and right eye gives blank adjuvant and compares.
Splash into 0.05-0.1ml, every day 1-2 time, 2 weeks of long run test at every turn.Behind 1h, 4h, 1d, 2d, 3d, 6d, 10d, the 14d, with slit lamp the rabbit eye is carried out the fluorescein sodium chromoscopy respectively before the administration and after the administration, record eye reaction score value after checking, the score value standard sees Table 1.Record simultaneously the ophthalmic injuries situation of observing.Stimulation situation score value standard sees Table 2.
Table 1
The evaluation of table 2 eye irritation
| The stimulation degree | Integration |
| Nonirritant | 0-3 |
| Slight zest | 4-8 |
| The moderate zest | 9-12 |
| The intensity zest | 13-16 |
Result of the test can see Table 3.
Table 3
As shown in Table 3, the bromfenac sodium hydrate eye drop to the cornea of new zealand rabbit, iris, conjunctiva without the obvious stimulation effect.
Application examples 2 clinical trials
The eye drop that sample 1 makes for embodiment 2, the eye drop that sample 2 makes for embodiment 3.
The I clinical trial phase
Implement first the nonclinical test result, the clinical valid density of bromfenac sodium is 0.1wt%～0.2wt%.The I clinical trial phase sample 1 that carries out, sample 2 be 1 time 2, eye dripping single-dose test, after the real-time reaction safety confirmed, with 4 times on the 1st, repeated administration test between 4 weeks.Single-dose test is felt the finding no abnormality seen from patient.Repeated administration test, outer eye finding, visible point at the moment excitement and is crossed the outer eye findings such as the property conjunctiva palpebrae is rubescent and is changed, without disposing an also visible similar variation, in physiological or common eye dripping range.Hematological examination, color have rising, for changing in normal range.Vision, pupil footpath, intraocular pressure, ERG, blood pressure, pulse frequency, be showed no ANOMALOUS VARIATIONS.And, bromfenac sodium blood level behind the eye dripping, during each measuring point all below detection limit (50ng/mL).
Early stage the II clinical trial phase
Early stage the II clinical trial phase, take post-operation inflammatory, anterior in the patient of ophthalmia as object, adopt sample 1 with medicine-feeding test between 4 times on the 1st 2 weeks.In addition, the clinical trial of this product anti-inflammatory effect comparison, with same mechanism of action, externally eye inflammation and anterior interior ophthalmia have extensive usefulness, the pranoprofen eye drop (available from Shandong seamount pharmaceutcal corporation, Ltd) that clinical serviceability is established is the contrast medicine, infers that from this product concentration basic test clinical bromfenac sodium valid density setting 0.1% compares detection.Pranoprofen is 41.5% (22/53), and sample 1 is 58.3% (35/60), and the clinical effectiveness of sample 1 is better than contrasting medicine.And the objective appraisal of inflammation finding is measured anterior chamber's albumen (flicker value) amount passing value based on laser isotope and is judged.Its result, the clinical effectiveness of 1 pair of post-operation inflammatory of sample is better than pranoprofen.Security inspection, the drug-induced side effect has no, intraocular pressure and the change of blood test no abnormality seen.
Later stage II clinical trial phase
With carrying out behind the II clinical trial phase result early stage, carry out law of application and dosetest take the post-operation inflammatory patient as object.
1, the eye dripping number of times detects
Early stage, II clinical trial phase sample 1 was better than pranoprofen with 4 times on the 1st eye dripping clinical effectiveness, now compared test with sample 1 with 2 times on the 1st eye dripping and 4 eye dripping.Each 2 eye dripping of whole degree of improvement and 4 eye dripping clinical effectiveness have no difference, 4 whole degree of improvement 58.8% (30/51) of eye dripping group, 2 eye dripping groups 59.3% (32/54).4 times eye dripping group side effect discovery rate is 5.2% (3/58), and the side effect of 2 eye dripping groups has no (0/58), 4 relative 2 eye dripping group side effect discovery rates of eye dripping group raise and are inclined to (p
0=0.0793).Above result draws, and this product eye dripping number of times is appropriate 2 times on the 1st.
2, to suitable concentration detection
The valid density of clinical deduction bromfenac sodium is 0.1%, the safety of high concentration I clinical trial phase confirms as 0.2%, and the pranoprofen eye drop of low concentration and nonclinical test 0.1% is with 3 groups of comparative tests of bromfenac sodium of 0.01% of degree anti-inflammatory effect.In addition, passing is judged based on slit lamp microscope anterior chamber albumen finding.0.01% bromfenac sodium is 63.9% (46/72), 0.1% bromfenac sodium is that 90.1% (64/71), 0.2% bromfenac sodium is 85.5% (59/69), and 0.1% and 0.2% bromfenac sodium clinical effectiveness is better than 0.01% statistical significance.Clinical effectiveness has no difference (p between 0.1% and 0.2% bromfenac sodium
0=0.5431).Security inspection, the severe side effect has no, and the bromfenac sodium of corneal epithelium infringement this product concentration 0.01% is that 1 example, 0.1% bromfenac sodium are that 2 examples, 0.2% bromfenac sodium are 1 example, has no concentration interdependence relation.Above result draws, bromfenac sodium to the usage of eye local inflammation illness and dosage take 2 times on the 1st eye dripping of 0.1% concentration as appropriate.
And the intraocular lens inserts art and is implemented as before the subject patient art in the single-dose art mydriasis and keeps effect and the research of combined postoperative disease open trial.But, relate to main evaluation index platycoria and keep effect and do not obtain sufficient measurement result.Have no side effect due to this product.
The clinical comparative test of III phase
The result draws from later stage II clinical trial phase, sample 1 carries out more objective appraisal with 2 times on the 1st eye dripping this product anti-inflammatory effects, do the contrast medicine with the clinical NSAID (non-steroidal anti-inflammatory drug) pranoprofen eye drop (available from Shandong seamount pharmaceutcal corporation, Ltd) of frequent use, carry out arranging the comparative study of double blind check method more.To post-operation inflammatory, accumulation effective percentage pranoprofen group is 67.6% (71/105), and the bromfenac sodium group is 83.8% (88/105), and the clinical effectiveness of bromfenac sodium is more excellent.And accumulation effective percentage pranoprofen group is 60.3% (47/78), and the bromfenac sodium group is 76.2% (64/84), and the clinical effectiveness of bromfenac sodium is excellent than the pranoprofen group.Side effect discovery rate, pranoprofen group are 1.8% (2/112), the bromfenac sodium group is 0.9% (1/114).The accumulation effective percentage of external eye inflammation illness (blepharitis, conjunctivitis, keratitis, scleritis and upper scleritis), the pranoprofen group is 54.7% (52/95), the bromfenac sodium group is 63.4% (59/93), has no significant difference (p
0=0.7158).But congruency check, this product are to pranoprofen congruency probatio inspectionem pecuoarem Δ=10%.Side effect discovery rate pranoprofen group is 2.9% (3/105), and the bromfenac sodium group is 6.9% (7/102).In addition, have no this product side effect, pain when side effect only only limits to eye dripping, ophthalmalgia (pranoprofen group 2 examples, bromfenac sodium group 3 examples).
The general clinical trial of III phase
The general clinical experimental study of the effectiveness and reliability of sample 2 external eye inflammation and anterior interior ophthalmia.
291 patients have been carried out double blind controling test, dosage 1 time 1,2 times on the 1st, in 2 weeks of medication, the result shows efficient (effectively) and is respectively blepharitis 66.7% (6/9), conjunctivitis 63.2% (60/95), scorching (it is scorching to contain strong film) 63.6% (7/11) of strong film and post-operation inflammatory 86.4% (152/291).
Two have respectively that 296 and 231 patients participate at random, in the double blinding, placebo controlled clinical trial, patient's medication 14 days, estimated curative effect of medication at the 15th day, patient's eyes inflammation clearance rate (terminal point is patient's proportion of ocular infection complete obiteration) is respectively 62.6% and 65.8%.
In addition in a research, sample 2 external eye inflammation (blepharitis 1 example, conjunctivitis 20 examples, scleritis and upper scleritis 2 examples) accumulation effective percentage is 60.9% (14/23), corneal erosion, titillation, each 1 example meter 3 example (11.5%) of blepharitis have no the unusual side effect of severe in side effect 26 examples.
In sum, the present invention is a kind of the most effective cyclooxygenase-2 inhibitors of high selectivity, good effectiveness and safety are arranged, clinical blepharitis, conjunctivitis, scleritis (containing scleritis), the post-operation inflammatories etc. of being mainly used in are the important drugs of the outer eye of symptomatic treatment and front eye inflammation illness.
Claims (5)
1. the bromfenac sodium hydrate eye drop is characterized in that, its composition and weight proportion are counted with 100%, bromfenac sodium hydrate 0.1～0.2%, Tween 80 is 0.1～0.3%, polyvidone 1～5%, disodium edetate 0.01～0.03%, anhydrous sodium sulfite 0.2～0.5%, benzalkonium bromide 0.01～0.02%, boric acid 0.005-0.02%, Borax 0.005-0.02%, sodium hydroxide 0.002-0.01%, surplus is water.
2. bromfenac sodium hydrate eye drop according to claim 1, it is characterized in that, its composition and weight proportion are counted with 100%, bromfenac sodium hydrate 0.1035%, Tween 80 are 0.15%, polyvidone 2%, disodium edetate 0.02%, anhydrous sodium sulfite 0.2%, benzalkonium bromide 0.01%, boric acid 0.02%, Borax 0.02%, sodium hydroxide 0.005%, and surplus is water.
3. bromfenac sodium hydrate eye drop according to claim 1 is characterized in that, described water is water for injection.
4. the preparation method of bromfenac sodium hydrate eye drop is characterized in that, specifically preparation process is,
(1) dense joining: in dense preparing tank, add the water that accounts for water gross weight 1/5-1/3, the bromfenac sodium hydrate, Tween 80, disodium edetate, anhydrous sodium sulfite, the benzalkonium bromide that add simultaneously the described formula ratio of claim 1, be stirred to evenly, leave standstill 30-60min and filter by filter, filtrate is delivered to dilute preparing tank;
(2) rare joining: in dilute preparing tank, add the water that accounts for water gross weight 1/4-1/2, the boric acid, Borax, the polyvidone that add simultaneously the described formula ratio of claim 1, the surplus water is supplied, and adds the pH=8.0-8.6 of sodium hydroxide regulation system, continue to stir 20-40 minute even to medicinal liquid;
(3) check, filtration sterilization, embedding, lamp inspection, packing, full inspection.
5. the preparation method of bromfenac sodium hydrate eye drop according to claim 4 is characterized in that, the described filtration sterilization operation of step (3) is selected microporous filter membrane, and the aperture is 0.22～0.45 μ m.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102787484A CN102988278A (en) | 2011-09-19 | 2011-09-19 | Bromfenac sodium hydrate eye drops and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102787484A CN102988278A (en) | 2011-09-19 | 2011-09-19 | Bromfenac sodium hydrate eye drops and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102988278A true CN102988278A (en) | 2013-03-27 |
Family
ID=47917712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102787484A Pending CN102988278A (en) | 2011-09-19 | 2011-09-19 | Bromfenac sodium hydrate eye drops and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102988278A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523587A (en) * | 2014-12-31 | 2015-04-22 | 辰欣药业股份有限公司 | Bromfenac sodium eye drops and preparation method thereof |
| CN108853074A (en) * | 2017-05-10 | 2018-11-23 | 武汉先路医药科技股份有限公司 | A kind of pharmaceutical aqueous eye drops and preparation method thereof containing bromfenac sodium hydrate |
| CN111743858A (en) * | 2019-03-29 | 2020-10-09 | 天津药业研究院有限公司 | Pharmaceutical composition of bromfenac sodium |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823754A (en) * | 2006-03-28 | 2006-08-30 | 卢秀莲 | Sodium bromophenolate eye drops and its preparation method |
| CN101313899A (en) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | Medicament composition for eyes containing sodium bromfenac |
| CN101322683A (en) * | 2008-07-30 | 2008-12-17 | 宛六一 | Gel for eye containing bromfenac sodium hydrate and preparation thereof |
-
2011
- 2011-09-19 CN CN2011102787484A patent/CN102988278A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823754A (en) * | 2006-03-28 | 2006-08-30 | 卢秀莲 | Sodium bromophenolate eye drops and its preparation method |
| CN101313899A (en) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | Medicament composition for eyes containing sodium bromfenac |
| CN101322683A (en) * | 2008-07-30 | 2008-12-17 | 宛六一 | Gel for eye containing bromfenac sodium hydrate and preparation thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523587A (en) * | 2014-12-31 | 2015-04-22 | 辰欣药业股份有限公司 | Bromfenac sodium eye drops and preparation method thereof |
| CN108853074A (en) * | 2017-05-10 | 2018-11-23 | 武汉先路医药科技股份有限公司 | A kind of pharmaceutical aqueous eye drops and preparation method thereof containing bromfenac sodium hydrate |
| CN111743858A (en) * | 2019-03-29 | 2020-10-09 | 天津药业研究院有限公司 | Pharmaceutical composition of bromfenac sodium |
| CN111743858B (en) * | 2019-03-29 | 2023-06-27 | 天津药业研究院股份有限公司 | Pharmaceutical composition of bromfenac sodium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6060168B2 (en) | An anterior eye disease therapeutic agent comprising rebamipide and a drug having a lacrimal fluid retention action | |
| CN103998034A (en) | Use of omega fatty acids for treating disease | |
| CN103040888A (en) | Ophthalmologic external preparation, as well as preparation method and application thereof | |
| CN114469851A (en) | Diquafosol sodium eye temperature-sensitive gel and preparation method thereof | |
| CN103566068A (en) | Compound composition with retina protection function and application thereof | |
| CN102988278A (en) | Bromfenac sodium hydrate eye drops and preparation method thereof | |
| CN100522162C (en) | New pranoprofen eye drops and its preparation method | |
| KR20220079480A (en) | Pharmaceutical composition comprising sglt-2 inhibitor for preventing or treating diabetic opthalmopathy disease | |
| CN100569218C (en) | Benzydalysine eye drop and preparation method thereof | |
| KR20150126021A (en) | Compositions for use in treating eye disorders using dipyridamole | |
| CN103327981A (en) | Methods for treating diseases of the retina | |
| CN102008488A (en) | Triamcinolone acetonide ophthalmic preparation and preparation method thereof | |
| US20230364047A1 (en) | Use of ester group-containing aromatic propionamide compound in preparation of medicine for treating dry eye syndrome | |
| RU2662364C2 (en) | Method for cataract treatment and eye drops for implementation thereof | |
| CN100563628C (en) | A kind of Bendalysine eye gel preparation and preparation method thereof | |
| CN111450054B (en) | Ophthalmic preparation containing caffeic acid ester, preparation method and application | |
| CN101797223A (en) | Huperzine A preparations for eyes and application thereof | |
| US11426346B2 (en) | Lutein-containing ophthalmic composition | |
| CN105147709B (en) | A kind of purposes of tenofovir dipivoxil or its pharmaceutical salts | |
| CN107320446A (en) | A kind of forsythin eye drops and preparation method thereof | |
| CN105012404A (en) | Eye drop for treating xerophthalmus and preparation method of eye drop | |
| Sahu et al. | Role of zinc-aspirin metal coordination complex in diabetic cataract induced in vitro in goat eye lens | |
| CN115708800A (en) | Eye drop composition of sitagliptin and tea polyphenol | |
| CN106344499A (en) | FTY720 eye drops and preparation method and application thereof | |
| CN114191441B (en) | Application of pulsatilla saponin B5 in preparation of medicine for treating wet macular degeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130327 |